SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies surges on partnering with West Pharmaceutical Services to launch Cloti-Xa in India

13 Apr 2021 Evaluate

Venus Remedies is currently trading at Rs. 289.65, up by 13.75 points or 4.98% from its previous closing of Rs. 275.90 on the BSE.

The scrip opened at Rs. 284.00 and has touched a high and low of Rs. 289.65 and Rs. 270.00 respectively. So far 12546 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 314.10 on 24-Mar-2021 and a 52 week low of Rs. 28.35 on 13-Apr-2020.

Last one week high and low of the scrip stood at Rs. 302.85 and Rs. 270.00 respectively. The current market cap of the company is Rs. 336.69 crore.

The promoters holding in the company stood at 35.89%, while Institutions and Non-Institutions held 0.04% and 64.07% respectively.

Venus Remedies has inked partnership with West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, for its new introduction in the fast-growing low molecular weight heparin market with brand Cloti-Xa, which has adopted NovaGuard SA Pro safety system, a single-use accessory for prefilled ISO standard 1mL long staked-needle syringes.

Cloti-Xa which contains enoxaparin sodium is being introduced with added advantage of NovaGuard SA Pro safety system which is a revolutionary product that helps and protects healthcare workers and patients from accidental needle stick injuries. This innovative product has been commented to deliver a compelling total cost of ownership in that it prevents pre-activation, offers a lower syringe snap-in force and a lower activation force for end-user comfort, and mitigates the practice of recapping which helps to provide tamper evidence to customers.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. It has world-class manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and research and development center in Venus Medicine Research Centre (in India).

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×